DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
Recruiting · NCT05764057 · Registry updated 2025-12-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction | Infarction, Necrosis, Non-ST Elevated Myocardial Infarction, Pathologic Processes, Pathological Conditions, Signs and Symptoms, ST-elevation myocardial infarction, Ventricular Dysfunction, Ventricular Dysfunction, Left, cardiovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Recruiting | Phase 3 | 2025-12-19 | NCT05764057 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Assistance Publique - Hôpitaux de Paris | 985 |
| AstraZeneca | 806 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Department of Cardiology AP-HP Hôpital européen Georges - Pompidou | Paris | France | 1 |